WASHINGTON (dpa-AFX) - China Medical System Holdings Limited and Incyte
(INCY) announce that CMS Skinhealth, and Incyte entered into a Collaboration and
License Agreement for the development and commercialization of povorcitinib, a
selective oral JAK1 inhibitor, to research, develop, register and commercialize
the product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven
Southeast Asian countries and a non-exclusive license to manufacture the product
in CMS' Territory. CMS will receive an exclusive license to develop and
commercialize and a non-exclusive license to manufacture povorcitinib in
autoimmune and inflammatory dermatologic diseases.

CMS will make an upfront payment to Incyte. Incyte is eligible to receive
additional potential development and commercial milestones and royalties on net
sales of the licensed product in CMS' territory.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX